邻氯苯基氯化镁 | 1034156-02-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻氯苯基氯化镁
• 英文名称: o-chlorophenylmagnesium chloride
• 英文别名: (2-chlorophenyl)magnesium chloride
• CAS: 1034156-02-9
• 化学式: C₆H₄Cl₂Mg
• 分子量: 171.309
• InChiKey: LMWRUVZWLBOLRD-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.82
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  邻氯苯基氯化镁 在 copper(l) iodide 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 5.5h， 生成 4-(2-chlorophenyl)-3-(isopropoxycarbonyl)-5-(methoxycarbonyl)-1-methyl-1,4-dihydropyridine
  参考文献：
  名称：

  Synthesis of 4-functionalized aryl-3,5-diacyl-1,4-dihydropyridines

  摘要：

  The valuable N-unsubstituted 4-aryl-3,5-diacyl-1,4-dihydropyridines 12b-f, bearing an electron-withdrawing substituent at the benzene ring, have been synthesized by the copper-mediated addition of functionalized arylmagnesium reagents 2b-f to N-benzhydrylpyridinium salt 9, followed by acylation with trichloroacetic anhydride and the subsequent haloform reaction and N-deprotection. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00941-9
• 作为产物：
  描述：

  2-溴氯苯 在 异丙基氯化镁 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 邻氯苯基氯化镁
  参考文献：
  名称：

  一种高纯度盐酸艾司氯胺酮酮体的制备方法

  摘要：

  本发明公开了一种高纯度盐酸艾司氯胺酮酮体的制备方法，所述盐酸艾司氯胺酮酮体的结构如式(I)所示；所述制备方法以环戊酸和邻氯溴苯为起始物料，经过酰氯化反应、金属化反应以及格氏反应，合成盐酸艾司氯胺酮酮体；本发明获得的盐酸艾司氯胺酮酮体具有纯度高，收率高，可应用于盐酸艾司氯胺酮原料药的制备等特点。

  公开号：

  CN112299972B
• 作为试剂：
  描述：

  Methyl 1-[tert-butyl(dimethyl)silyl]pyridin-1-ium-3-carboxylate;trifluoromethanesulfonate 在 邻氯苯基氯化镁 作用下， 生成 烟酸甲酯
  参考文献：
  名称：

  Synthesis of 4-functionalized aryl-3,5-diacyl-1,4-dihydropyridines

  摘要：

  The valuable N-unsubstituted 4-aryl-3,5-diacyl-1,4-dihydropyridines 12b-f, bearing an electron-withdrawing substituent at the benzene ring, have been synthesized by the copper-mediated addition of functionalized arylmagnesium reagents 2b-f to N-benzhydrylpyridinium salt 9, followed by acylation with trichloroacetic anhydride and the subsequent haloform reaction and N-deprotection. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00941-9

文献信息

• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES À UTILISER DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：EUROSCREEN SA

  公开号：WO2015078949A1

  公开（公告）日：2015-06-04

  The present invention is directed to compounds of formula (I), useful in treating and/or preventing inflammatory diseases.

  本发明涉及一种化合物，其化学式为(I)，用于治疗和/或预防炎症性疾病。
• [EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUE CONDENSÉ COMME MODULATEURS DE L'ACTIVITÉ DU TNF
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2015086526A1

  公开（公告）日：2015-06-18

  A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列融合的三环咪唑衍生物，特别是二氢-1H-环戊[4,5]咪唑[1,2-a]吡啶衍生物及其类似物，作为人类肿瘤坏死因子α活性的强力调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• Method of preparing organomagnesium compounds
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP1582523A1

  公开（公告）日：2005-10-05

  The present invention is directed to a reagent for use in the preparation of organomagnesium compounds as well as to a method of preparing such organomagnesium compounds. The present invention furthermore provides a method of preparing functionalized or unfunctionalized organic compounds as well as the use of the reagents of the present invention in the preparation of organometallic compounds and their reaction with electrophiles. Finally, the present invention is directed to the use of lithium salts - LiY in the preparation of organometallic compounds and their reactions with electrophiles and to an organometallic compound which is obtainable by the disclosed method.

  本发明涉及一种试剂，用于制备有机镁化合物，以及一种制备这种有机镁化合物的方法。本发明还提供了一种制备官能化或非官能化有机化合物的方法，以及本发明的试剂在制备有机金属化合物及其与亲电试剂反应中的应用。最后，本发明涉及锂盐LiY在制备有机金属化合物及其与亲电试剂反应中的应用，以及通过所披露方法获得的有机金属化合物。
• [EN] PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR APPLICATION AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：EUROSCREEN SA

  公开号：WO2011073376A1

  公开（公告）日：2011-06-23

  The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

  本发明涉及具有式（I）的新化合物，以及它们在治疗和/或预防代谢性疾病中的用途。
• Chemical compounds 572
  申请人：Berger Markus

  公开号：US20080214641A1

  公开（公告）日：2008-09-04

  Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

  化合物公式（I）：本发明涉及新型吲唑酯或酰胺衍生物，涉及包含这些衍生物的制药组合物，涉及制备这些新型衍生物的过程，以及将这些衍生物用作药物的用途。